Fujian Haixi Pharmaceuticals Co (HKSE:02637) PEG Ratio: N/A (As of Aug. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02637 Fujian Haixi Pharmaceuticals Co Ltd HKSE:02637
23 GF Score
Price HK$204.80
! 2 Warning Signs
View Full Analysis

What is Fujian Haixi Pharmaceuticals Co PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Fujian Haixi Pharmaceuticals Co's PE Ratio without NRI is 70.33. Fujian Haixi Pharmaceuticals Co's 5-Year EBITDA growth rate is 0.00%. Therefore, Fujian Haixi Pharmaceuticals Co's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Fujian Haixi Pharmaceuticals Co's PEG Ratio or its related term are showing as below:



HKSE:02637's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.81
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.

Fujian Haixi Pharmaceuticals Co  (HKSE:02637) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.

Fujian Haixi Pharmaceuticals Co PEG Ratio Related Terms

Fujian Haixi Pharmaceuticals Co PEG Ratio Historical Data

* Premium members only.

The historical data trend for Fujian Haixi Pharmaceuticals Co's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fujian Haixi Pharmaceuticals Co PEG Ratio Chart

Fujian Haixi Pharmaceuticals Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
PEG Ratio
0.00 0.00 0.00 0.00

Fujian Haixi Pharmaceuticals Co Semi-Annual Data
Dec22 Dec23 Dec24 Dec25
PEG Ratio 0.00 0.00 0.00 0.00

HKSE:02637 vs ZTS: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Fujian Haixi Pharmaceuticals Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fujian Haixi Pharmaceuticals Co PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fujian Haixi Pharmaceuticals Co's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Fujian Haixi Pharmaceuticals Co's PEG Ratio falls into.


HKSE:02637
23GF Score
Fujian Haixi Pharmaceuticals Co Ltd HKSE:02637
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fujian Haixi Pharmaceuticals Co PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Fujian Haixi Pharmaceuticals Co's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=70.32967032967/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Fujian Haixi Pharmaceuticals Co Business Description

Address No. 177 Jinda Road, Floor 3rd & 4th, Block B, Jianxin Town, Cangshan District,Fujian Province, Fuzhou, CHN, 350028
Fujian Haixi Pharmaceuticals Co Ltd is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of inventive drug candidates. It has a diversified product portfolio and pipeline in the fastest growing therapeutic areas in China. The company's commercialized product portfolio consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. Its inventive drug pipeline focuses on drug candidates in a variety of indications, including one potential first-in-class oncology drug candidate, one potential first oral drug therapy for wet age-related macular degeneration /diabetic macular edema /retinal vein occlusion.
23GF Score

Get the complete analysis for HKSE:02637

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$204.80
Price